For research use only. Not for therapeutic Use.
NADH-IN-1 has NADH:ubiquinone oxidoreductase inhibitory activity with an IC50 value of 27 μM. NADH-IN-1 can effectively stimulate glucose uptake in vitro. NADH-IN-1 is readily metabolised by the liver. NADH-IN-1 can be used for researching diabetes[1].
NADH-IN-1 (1 μM) exhibits a short half-life and fast intrinsic clearance indicating that it is readily metabolised by the liver in vivo; shows no adverse effects on primary rat hepatocytes, and does not inhibit the hERG channel[1].
NADH-IN-1 (10 mg/kg; IV or PO; single dosage) produces no observable toxic effects at 10 mg/kg by IV or PO; exhibits a short half-life and high plasma clearance; exhibits high mouse and human serum protein binding, as well as moderate bioavailability[1].
| Catalog Number | I043696 |
| CAS Number | 1432445-15-2 |
| Synonyms | 4-thiophen-2-yl-1-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]butan-1-one |
| Molecular Formula | C19H21F3N2OS |
| Purity | ≥95% |
| InChI | InChI=1S/C19H21F3N2OS/c20-19(21,22)15-6-8-16(9-7-15)23-10-12-24(13-11-23)18(25)5-1-3-17-4-2-14-26-17/h2,4,6-9,14H,1,3,5,10-13H2 |
| InChIKey | KJARPKCKZJCRAS-UHFFFAOYSA-N |
| SMILES | C1CN(CCN1C2=CC=C(C=C2)C(F)(F)F)C(=O)CCCC3=CC=CS3 |
| Reference | [1]. Devine R, et al. Design, synthesis, and biological evaluation of aryl piperazines with potential as antidiabetic agents via the stimulation of glucose uptake and inhibition of NADH:ubiquinone oxidoreductase. Eur J Med Chem. 2020;202:112416. |
